{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"1"},{"groupId":"OG001","spread":"0.27","value":"1.33"},{"groupId":"OG002","spread":"0.13","value":"1.29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"description":"Xerostomia will be assessed using Maximum Xerostomia Clinical Score Common Terminology Criteria for Adverse Events (CTCAE) 4.03. Scores range from 0 to 5 with 0 being no xerostomia and 5 being the worst. Mean maximum xerostomia grade of patients assessed is reported.","dispersionType":"Standard Error","groups":[{"description":"Subjects were administered a 7 mg loading dose subcutaneously followed by a 3.5 mg maintenance dose subcutaneously twice a week while on concurrent cisplatin and RT.","id":"OG000","title":"Phase 1: Group 1"},{"description":"Subjects were administered a 14 mg loading dose subcutaneously followed by a 7 mg maintenance dose subcutaneously twice a week while on concurrent cisplatin and RT.","id":"OG001","title":"Phase 1: Group II"},{"description":"Subjects were administered a 28 mg loading dose subcutaneously followed by a 14 mg maintenance dose subcutaneously twice a week while on concurrent cisplatin and RT.","id":"OG002","title":"Phase 2: Group III"}],"paramType":"MEAN","populationDescription":"One subject in group 3 did not complete follow up and was excluded from the analysis (a score of 0 representing no xerostomia)","reportingStatus":"POSTED","timeFrame":"6 months","title":"Incidence of Radiation-induced Xerostomia by Clinician Scoring","type":"SECONDARY","unitOfMeasure":"score on a scale"}